All In Biotech

Drug Trial Radar · NCT03992755

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

A Global, Open-Label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients

Last checked: Nov 20, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

92

Actual

Start

Jul 18, 2019

Primary completion

May 31, 2025

Study completion May 31, 2025

Sponsor

Lead sponsor
Liquidia Technologies, Inc.Industry
Sponsor type
Industry
Collaborators
Nuventra, Inc.
First posted
Jun 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).

Conditions

  • Primary Pulmonary Hypertension

Interventions

  • LIQ861 Inhaled TreprostinilDrug

    LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse events (AEs).Time frame: Baseline until the end of study, approximately 2.5 years (Dec-2021).

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center

    Phoenix, Arizona

  • Arizona Pulmonary Specialists, Ltd.

    Phoenix, Arizona

  • West Los Angeles VA Healthcare Center

    Los Angeles, California

  • UC Davis Medical Center

    Sacramento, California

  • Los Angeles Biomedical Research Center

    Torrance, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • University of Florida

    Gainesville, Florida

  • Mayo Clinic-Jacksonville

    Jacksonville, Florida

  • AdventHealth

    Orlando, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Northwestern Medicine, Feinberg School of Medicine

    Chicago, Illinois

  • University of Chicago Medicine

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Tufts Medical Center

    Boston, Massachusetts

  • Mayo Clinic-Rochester

    Rochester, Minnesota

  • University of New Mexico Health Science Center

    Albuquerque, New Mexico

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Oregon Health and Science Center

    Portland, Oregon

  • Alleghany General Hospital

    Pittsburgh, Pennsylvania

  • UPMC Presbyterian Hospital

    Pittsburgh, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • Houston Methodist Lung Center

    Houston, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • INOVA Fairfax Medical Campus

    Falls Church, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.